scholarly journals The Impact of Mismatch Repair Status on Prognosis of Patients With Gastric Cancer: A Multicenter Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Wen-Long Guan ◽  
Yue Ma ◽  
Yue-Hong Cui ◽  
Tian-Shu Liu ◽  
Yan-Qiao Zhang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Mismatch Repair ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Clinicopathological Characteristics ◽  
Her2 Status ◽  
Clinical Role ◽  
Record System ◽  
Free Survival ◽  
The Impact

BackgroundThe clinical role of deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) in gastric cancer (GC) is still controversial. We aimed to analyze the relationship between dMMR/MSI-H and clinicopathological features along with survival.MethodsPatients who were diagnosed with GC at the three big cancer centers in China from 2015 to 2020 were evaluated retrospectively. MMR/MSI status was assessed using immunohistochemistry/PCR. Clinical and pathological data were collected from the medical record system.ResultsA total of 196 patients with dMMR/MSI-H status were enrolled for analysis. The prevalence of MSI-H/dMMR in GC was 6.6%. Another 694 proficient MMR (pMMR) GC patients were enrolled for comparison. Compared with pMMR patients, dMMR/MSI-H patients were associated with older age, female predominance, distal location in the stomach, earlier TNM stage, intestinal subtype, better differentiation, and more negative HER2 status. The median overall survival (OS) of the dMMR/MSI-H group was better than that of the pMMR/microsatellite stability (MSS) group (not reached vs. 53.9 months, p = 0.014). Adjuvant chemotherapy had no impact in both disease-free survival (DFS) and OS of dMMR/MSI-H patients (p = 0.135 and 0.818, respectively). dMMR/MSI-H patients had poorer response and progression-free survival (PFS) of first-line chemotherapy, though they were statistically significant (p = 0.361 and 0.124, respectively).ConclusionsdMMR/MSI-H GC patients have specific clinicopathological characteristics and better prognosis than pMMR patients.

scholarly journals Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients

Biomolecules ◽  
2019 ◽  
Vol 9 (12) ◽  
pp. 782
Author(s):  
Jiwon Koh ◽  
Soo Kyung Nam ◽  
Youn Woo Lee ◽  
Jin Won Kim ◽  
Keun-Wook Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Univariate Analysis ◽  
Growth Factor Receptor ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Test Methods ◽  
Her2 Status ◽  
Her2 Receptor ◽  
Free Survival ◽  
Conventional Methods

While human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) antibodies bind to the intracellular domain, trastuzumab binds to the extracellular epitope of HER2 receptor: target of drug action. We aimed to evaluate clinical significance of the new IHC method assessing the target of trastuzumab in gastric cancer (GC) patients and compare with conventional methods. Sixty-nine trastuzumab-treated GC patients were enrolled from two different cohorts. Additionally, we enrolled 528 consecutive GC patients to evaluate prognostic implications of HER2 test methods. HER2 status was assessed by trastuzumab IHC, HER2 IHC (4B5), and HER2 silver in situ hybridization (SISH). HER2 IHC showed 3+ in 48/69 trastuzumab-treated patients (69.6%), however, trastuzumab IHC showed 3+ in 25 (36.2%). Patients with trastuzumab IHC ≥2+ had significantly better progression-free survival (PFS) and overall survival (OS) than their counterpart (p = 0.014). In univariate analysis, trastuzumab IHC ≥2+ and HER2 IHC 3+ were only significant predictive factors for OS in trastuzumab-treated patients. Of the 528 consecutive GCs, patients with trastuzumab IHC ≥2+ had shorter disease-free survival (DFS) and OS (p = 0.008 and 0.031, respectively), while conventional methods failed to reveal any significant survival differences. HER2 assessment by trastuzumab IHC was different from conventional HER2 test results. Trastuzumab IHC was suggested to be a significant predictive factor for trastuzumab responsiveness and prognostic factor for consecutive GCs.

Association of dynamic changes of methylated SFRP2 in ctDNA with prognosis in advanced gastric cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e15051-e15051
Author(s):  
Yan Haijiao ◽  
Kele Ge ◽  
Wenyu Chen ◽  
Xizheng Mao ◽  
Xiaodong Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Dynamic Change ◽  
Disease Free Survival ◽  
Stage Iv ◽  
Progression Free Survival ◽  
Suppressor Gene ◽  
Stage Iii ◽  
Dynamic Monitoring ◽  
Free Survival ◽  
Potential Biomarker

e15051 Background: Secreted frizzled-related protein 2 (SFRP2) is a tumor suppressor gene and its hyper methylation could cause its inactivation and promote cancer development. However, whether methylated SFRP2 (mSFRP2) in ctDNA could serve as prognostic biomarker for patients with gastric cancer has not been thoroughly studied. Methods: Stage III or IV gastric cancer patients treated with systemic chemotherapy in the Third Affiliated Hospital of Soochow University from 2015 to 2017 were included. The mSFRP2 before and during chemotherapy were dynamically detected from ctDNA by digital polymerase chain reaction-based technologies. Results: In total, 121 patients were enrolled, with 63 in stage III and 58 in stage IV. Baseline median mSFRP2 was higher in stage IV than stage III (64 VS 18 copies/ng, P < 0.001). In stage III GC, the top 50% mSFRP2 population had shorter median disease-free survival (DFS, 11.0 months VS NR; HR, 13.05; 95% CI, 3.05-55.95;) and overall survival (OS, 17.0 months VS NR; HR, 7.80; 95% CI, 1.81-33.60). Similar results were observed in stage IV GC that the median progression-free survival (PFS, 4.0 VS 7.0 months; HR, 2.74; 95% CI, 1.58-4.78) and OS (12.0 VS 16.0 months; HR, 3.14; 95% CI, 1.67-5.92) was shorter in patients with top 50% mSFRP2. During the dynamic monitor along treatment, elevated mSFPR2 was associated with worse PFS (5.0 VS 7.0 months; HR, 2.17; 95% CI, 1.25-3.76) and OS (12.0 VS 15.5 months; HR, 3.51; 95% CI, 1.94-6.35) in stage IV patients. Conclusions: Our study shows the association between SFRP2 methylation and its dynamic change and prognosis in patients with gastric cancer. Our results provide a potential biomarker in ctDNA for prognosis and dynamic monitoring in patients with gastric cancer.

The impact of single-hetero UGT1A1 on clinical outcomes of irinotecan monotherapy in gastric cancer after fluoropyrimidine, platinum, and taxanes: Multicenter retrospective study.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 296-296
Author(s):  
Ken Ito ◽  
Yoshito Komatsu ◽  
Satoshi Yuki ◽  
Shintaro Nakano ◽  
Hiroshi Nakatsumi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Treatment Guidelines ◽  
Performance Status ◽  
Dose Intensity ◽  
Progression Free Survival ◽  
Her2 Status ◽  
Gastric Cancer Treatment ◽  
Third Line ◽  
The Impact

296 Background: Japanese gastric cancer treatment guidelines (5th edition) recommend irinotecan (IRI) after fluoropyrimidine, platinum and taxanes as a third line chemotherapy. We previously reported that patients with UGT1A1 single heterozygous (SH) had significantly high frequency of severe hematological adverse events (AEs) compared to patients with UGT1A1 wild type (WT) in IRI monotherapy for advanced gastric cancer (AGC). However, it remains unclear that UGT1A1 SH affect efficacy and safety of IRI after fluoropyrimidine, platinum and taxanes compared to WT as a salvage line. Methods: We retrospectively analyzed the clinical data of patients who received IRI monotherapy after fluoropyrimidine, platinum and taxanes in the multi-institutional retrospective study. From January 2010 to December 2017, 69 eligible patients were registered from 8 centers in Japan. Results: Forty one patients with UGT1A1 WT and 28 patients with UGT1A1 SH were included in this study. In WT/SH patients, performance status 0/1/≥2 was 12/25/4 and 5/17/6, treatment line 3rd/4th or later was 33/8 and 26/2, HER2 status positive/negative was 12/29 and 5/23, respectively. In WT/SH patients, rate of initial dose reduction was 22 and 28% (P = 0.363), median relative dose intensity (RDI) was 82% and 80% (P = 0.309). Of 88 patients who have measurable lesions, the overall response rate (ORR) was 5.7% and 4.2% (P = 1.000), disease control rate (DCR) was 54% and 38% (P = 0.289). Median progression free survival was 3.2 and 2.1 months (HR 0.607, P = 0.058) and median overall survival from initial day of IRI monotherapy was 10.0 and 7.0 months (HR 0.618 P = 0.086). In WT/SH patients, severe hematological AEs (≥G3) were observed more frequently in patients with UGT1A1 SH (WT: 43% and SH: 68%, P = 0.050), although frequency of severe non-hematological AEs (≥G3) were not significantly different in both groups (13% and 25%, P = 0.211). Conclusions: Compared to UGT1A1 WT, UGT1A1 SH status may be associated with poor efficacy and be a risk factor of higher frequency of severe hematological AEs.

scholarly journals Prognostic significance of NDRG2 combined with EGFR-sensitizing mutations in lung adenocarcinoma

2020 ◽  
Author(s):  
Bo Yang ◽  
Linlin Ji ◽  
Yiling Feng ◽  
Xiao-Ping Li ◽  
Hong-Gang Zhou ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Prognostic Significance ◽  
Growth Factor Receptor ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Lung Parenchyma ◽  
Clinicopathological Characteristics ◽  
Free Survival ◽  
Positive Correlations ◽  
Lung Puncture

Abstract Background: N-myc downstream-regulated gene 2 (NDRG2) plays a substantial role in lung adenocarcinoma (LUAD). Epidermal growth factor receptor (EGFR)-sensitizing mutation could significantly improve prognosis in patients with LUAD. Here, we aimed to elucidate the prognostic value of NDRG2 combined with EGFR-sensitizing mutations in patients with LUAD. Methods: Lung parenchyma specimens obtained during surgery or CT-guide percutaneous lung puncture biopsy for the NDRG2 protein and EGFR genomic testing were obtained. Associations between NDRG2/EGFR and clinicopathological characteristics of patients with LUAD were extracted from the Tianjin First Central Hospital in China between June 2013 and June 2014. Results: The expression of NDRG2 was significantly decreased in patients with LUAD. Expressions of NDRG2 and EGFR-sensitizing mutations showed positive correlations with survival. Expression of NDRG2 and EGFR-sensitizing mutations were associated with the longer overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS). Advanced stages were significantly associated with low expression of NDRG2. In multivariate analysis, compared with other patients, NDRG2 (+)/EGFR (+) was independently associated with prolonged OS and PFS. Conclusion: NDRG2 combined with EGFR-sensitizing mutations might be valuable markers to evaluate the prognosis of LUAD patients.

scholarly journals Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Shengjie Sun ◽  
Huiyu Dong ◽  
Tao Yan ◽  
Junchen Li ◽  
Chao Liang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Poor Prognosis ◽  
Meta Analysis ◽  
Gynecological Cancer ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Cochrane Library ◽  
Poor Overall Survival ◽  
Free Survival ◽  
The Impact

Abstract Background Published studies present conflicting data regarding the impact of Thrombospondin-1 (TSP-1) expression on prognosis of various cancers . We performed this meta-analysis to clarify the preliminary predictive value of TSP-1. Methods Twenty-four studies with a total of 2379 patients were included. A comprehensive literature search was performed by using PubMed, Cochrane Library, Web of Science, Embase, and hand searches were also conducted of relevant bibliographies. Pooled hazard ratio s ( HRs ) with 95% confidence intervals ( CIs ) for patient survival and disease recurrence were initially identified to explore relationships between TSP-1 expression and patient prognosis. Results A total of 24 eligible studies were included in this meta-analysis. Our results showed that high level of TSP-1 was correlated significantly with poor overall survival ( OS ) (HR=1.40, 95% CI: 1.17~1.68). However, high TSP-1 expression predicted no significant impact on progression-free survival ( PFS )/ metastasis-free survival (MFS ) (HR=1.35, 95%CI: 0.87-2.10) and disease-free survival ( DFS )/ recurrence-free survival ( RFS ) (HR = 1.40, 95%CI: 0.77–2.53). In addition, we performed subgroup analyses which showed that high TSP-1 expression predicted poor prognosis in breast cancer and gynecological cancer. Conclusions Our findings indicated high TSP-1 expression may serve as a promising biomarker of poor prognosis and novel therapeutic target in cancers, especially in breast cancer and gynecological cancer.

scholarly journals Role of the initial degree of anaemia and treatment model in the prognosis of gastric cancer patients treated by chemotherapy: a retrospective analysis

2020 ◽  
Author(s):  
Wenhuan Li ◽  
Ji-Yu Zhang ◽  
Wen-Hui Liu ◽  
Xian-Xian Chen
Keyword(s):  
Gastric Cancer ◽  
Progression Free Survival ◽  
Treatment Method ◽  
Clinicopathological Characteristics ◽  
Free Survival ◽  
Initial Degree ◽  
Patient Prognosis ◽  
Gastric Cancer Patients ◽  
The Relationship

Abstract Background ：Anaemia is highly prevalent in gastric cancer (GC) patients. The role of initial haemoglobin levels in predicting the prognosis of GC patients treated by chemotherapy has not been well determined. Our present study aims to evaluate the relationship between the degree of anaemia and the overall survival (OS) and progression-free survival (PFS) of patients with GC. Methods: Our retrospective study enrolled 598 patients who were treated with chemotherapy when the recurrent or metastatic GCs were unsuitable for surgical resection. Univariate and multivariate analyses were performed to identify risk factors that had the potential to affect patient prognosis. Additionally, the relationship between clinicopathological characteristics, including treatment method, and degree of cancer related reduction in haemoglobin was further analysed. Results : Our results revealed that patients with HB ini level ≤ 80 g/L had a trend toward a shortened median OS and PFS ( p =0.009 and p =0.049, respectively). Interestingly, we also found that HB dec ≥30 g/L was associated with a significantly shortened median OS and PFS ( p =0.039 and p =0.001, respectively). Multivariate analysis showed that HB ini levels ≤80 g/L could be used as an independent prognostic factor for recurrent and metastatic GC. More importantly, HB dec ≥30 g/L and treatment response were also significantly associated with OS and PFS. Furthermore, the degree of haemoglobin decrease was associated with chemotherapy including platinum and the number of chemotherapy cycles. Conclusion : Our study concludes that the initial degree of anaemia and a decrease in haemoglobin of ≥ 30 g/L can serve as biomarkers to predict prognosis in recurrent or metastatic GC patients, while chemotherapy treatment rather than red blood cell (RBC) transfusion can improve their prognosis. Additionally, platinum should not be recommended for treating severely anaemic GC patients.

scholarly journals Role of the initial degree of anaemia and treatment model in the prognosis of gastric cancer patients treated by chemotherapy: a retrospective analysis

2019 ◽  
Author(s):  
Wenhuan Li ◽  
Ji-Yu Zhang ◽  
Wen-Hui Liu ◽  
Xian-Xian Chen
Keyword(s):  
Gastric Cancer ◽  
Progression Free Survival ◽  
Treatment Method ◽  
Clinicopathological Characteristics ◽  
Free Survival ◽  
Initial Degree ◽  
Patient Prognosis ◽  
Gastric Cancer Patients ◽  
The Relationship

Abstract Background: Anaemia is highly prevalent in gastric cancer (GC) patients. The role of initial haemoglobin levels in predicting the prognosis of GC patients treated by chemotherapy has not been well determined. Our present study aims to evaluate the relationship between the degree of anaemia and the overall survival (OS) and progression-free survival (PFS) of patients with GC. Methods: Our retrospective study enrolled 598 patients who were treated with chemotherapy when the recurrent GCs and metastatic GCs were unsuitable for surgical resection. Univariate and multivariate analyses were performed to identify risk factors that had the potential to affect patient prognosis. Additionally, the relationship between clinicopathological characteristics, including treatment method, and degree of chemotherapy-related reduction in haemoglobin was further analysed. Results: Our results revealed that patients with HBini level ≤ 80 g/L had a trend toward a shortened median OS and PFS (p=0.009 and p=0.049, respectively). Interestingly, we also found that HBdec ≥30 g/L was associated with a significantly shortened median OS and PFS (p=0.039 and p=0.001, respectively). Multivariate analysis showed that HBini levels ≤80 g/L could be used as an independent prognostic factor for recurrent and metastatic GC. More importantly, HBdec ≥30 g/L and treatment response were also significantly associated with OS and PFS. Furthermore, the degree of haemoglobin decrease was associated with chemotherapy including platinum and the number of chemotherapy cycles. Conclusion: Our study concludes that the initial degree of anaemia and a decrease in haemoglobin of ≥ 30 g/L can serve as biomarkers to predict prognosis in recurrent or metastatic GC patients, while chemotherapy treatment rather than red blood cell (RBC) transfusion can improve their prognosis. Additionally, paclitaxel should not be recommended for treating severely anaemic GC patients.

scholarly journals Role of the initial degree of anaemia and treatment model in the prognosis of gastric cancer patients treated by chemotherapy: a retrospective analysis

2020 ◽  
Author(s):  
Wenhuan Li ◽  
Ji-Yu Zhang ◽  
Wen-Hui Liu ◽  
Xian-Xian Chen
Keyword(s):  
Gastric Cancer ◽  
Progression Free Survival ◽  
Treatment Method ◽  
Clinicopathological Characteristics ◽  
Free Survival ◽  
Initial Degree ◽  
Patient Prognosis ◽  
Gastric Cancer Patients ◽  
The Relationship

Abstract Background：Anaemia is highly prevalent in gastric cancer (GC) patients. The role of initial haemoglobin levels in predicting the prognosis of GC patients treated by chemotherapy has not been well determined. Our present study aims to evaluate the relationship between the degree of anaemia and the overall survival (OS) and progression-free survival (PFS) of patients with GC.Methods: Our retrospective study enrolled 598 patients who were treated with chemotherapy when the recurrent or metastatic GCs were unsuitable for surgical resection. Univariate and multivariate analyses were performed to identify risk factors that had the potential to affect patient prognosis. Additionally, the relationship between clinicopathological characteristics, including treatment method, and degree of cancer-related reduction in haemoglobin was further analysed.Results: Our results revealed that patients with HBini level ≤ 80 g/L had a trend toward a shortened median OS and PFS (p=0.009 and p=0.049, respectively). Interestingly, we also found that HBdec ≥30 g/L was associated with a significantly shortened median OS and PFS (p=0.039 and p=0.001, respectively). Multivariate analysis showed that HBini levels ≤80 g/L could be used as an independent prognostic factor for recurrent and metastatic GC. More importantly, HBdec ≥30 g/L and treatment response were also significantly associated with OS and PFS. Furthermore, the degree of haemoglobin decrease was associated with chemotherapy including platinum and the number of chemotherapy cycles.Conclusion: Our study concludes that the initial degree of anaemia and a decrease in haemoglobin of ≥ 30 g/L can serve as biomarkers to predict prognosis in recurrent or metastatic GC patients, while chemotherapy treatment rather than red blood cell (RBC) transfusion can improve their prognosis. Additionally, platinum should not be recommended for treating severely anaemic GC patients.

scholarly journals Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Shengjie Sun ◽  
Huiyu Dong ◽  
Tao Yan ◽  
Junchen Li ◽  
Bianjiang Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Poor Prognosis ◽  
Meta Analysis ◽  
Gynecological Cancer ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Cochrane Library ◽  
Poor Overall Survival ◽  
Free Survival ◽  
The Impact

Abstract Background Published studies present conflicting data regarding the impact of Thrombospondin-1 (TSP-1) expression on prognosis of various cancers. We performed this meta-analysis to illustrate the preliminary predictive value of TSP-1. Methods Twenty-four studies with a total of 2379 patients were included. A comprehensive literature search was performed by using PubMed, Cochrane Library, Web of Science, Embase, and hand searches were also conducted of relevant bibliographies. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for patient survival and disease recurrence were initially identified to explore relationships between TSP-1 expression and patient prognosis. Results A total of 24 eligible studies were included in this meta-analysis. Our results showed that high level of TSP-1 was correlated significantly with poor overall survival (OS) (HR=1.40, 95% CI: 1.17~1.68; P＜0.001). However, high TSP-1 expression predicted no significant impact on progression-free survival (PFS)/ metastasis-free survival (MFS) (HR=1.35, 95%CI: 0.87-2.10; P=0.176) and disease-free survival (DFS)/ recurrence-free survival (RFS) (HR = 1.40, 95%CI: 0.77–2.53; P=0.271). In addition, we performed subgroup analyses which showed that high TSP-1 expression predicted poor prognosis in breast cancer and gynecological cancer. Additionally, the relatively small number of studies on PFS/MFS and DFS/RFS is a limitation. The data extracted through Kaplan-Meier curves may not be accurate. Moreover, only English articles were included in this article, which may lead to deviations in the results.Conclusions Our findings indicated high TSP-1 expression may act as a promising biomarker of poor prognosis in cancers, especially in breast cancer and gynecological cancer.

scholarly journals The impact of LncRNA dysregulation on clinicopathology and survival of pancreatic cancer: a systematic review and meta-analysis (PRISMA compliant)

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Elahe Seyed Hosseini ◽  
Ali Nikkhah ◽  
Amir Sotudeh ◽  
Marziyeh Alizadeh Zarei ◽  
Fatemeh Izadpanah ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Random Effects ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Free Survival ◽  
Diagnosis And Prognosis ◽  
The Impact ◽  
Disease Free

Abstract Purpose An increasing number of studies have reported a significant association between long non-coding RNAs (lncRNAs) dysregulation and pancreatic cancers. In the present study, we aimed to gather articles to evaluate the prognostic value of long non coding RNA in pancreatic cancer. Experimental design We systematically searched all eligible articles from databases of PubMed, Web of Science, and Scopus to meta-analysis of published articles and screen association of multiple lncRNAs expression with clinicopathology and/or survival of pancreatic cancer. The pooled hazard ratios (HRs) and their 95% confidence intervals (95% CIs) were used to analysis of overall survival, disease-free survival and progression-free survival were measured with a fixed or random effects model. Results A total of 39 articles were included in the present meta-analysis. Our results showed that dysregulation of lncRNAs were linked to overall survival (39 studies, 4736 patients HR = 0.41, 95% CI 0.25 ± 0.58, random-effects in pancreatic cancer. Moreover, altered lncRNAs were also contributed to progression-free survival (8 studies, 1180 patients HR: 1.88, 95% CI (1.35–2.62) and disease-free survival (2 studies, 285 patients, HR: 6.07, 95% CI 1.28–28.78). In addition, our findings revealed the association between dysregulated RNAs and clinicopathological features in this type of cancer. Conclusions In conclusion, dysregulated lncRNAs could be served as promising biomarkers for diagnosis and prognosis of pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document